Tribenzor and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is found among people who take Tribenzor, especially for people who are female, 50-59 old.

The phase IV clinical study analyzes which people take Tribenzor and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 1,732 people who have side effects when taking Tribenzor from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 16, 2022

1,732 people reported to have side effects when taking Tribenzor.
Among them, 6 people (0.35%) have Gastrointestinal inflammation.

What is Tribenzor?

Tribenzor has active ingredients of amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 1,772 Tribenzor users for its effectiveness, alternative drugs and more.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 772 drugs and 511 conditions by eHealthMe.

Number of Tribenzor and Gastrointestinal inflammation reports submitted per year:

Could Tribenzor cause Gastrointestinal inflammation?

Gender of people who have Gastrointestinal inflammation when taking Tribenzor *:

female: 100 %
male: 0.0 %

Age of people who have Gastrointestinal inflammation when taking Tribenzor *:

Common drugs people take besides Tribenzor *:

Common side effects people have besides Gastrointestinal inflammation *:

Blood Count Abnormal: 3 people, 50.00%
Neck Pain: 3 people, 50.00%
Dehydration (dryness resulting from the removal of water): 3 people, 50.00%
Diarrhea: 3 people, 50.00%
Hypotension (abnormally low blood pressure): 3 people, 50.00%
Weight Decreased: 2 people, 33.33%
Dysgraphia (impaired ability to learn to write): 2 people, 33.33%
Breast Pain: 2 people, 33.33%
Chest Pain: 2 people, 33.33%
Colitis (inflammation of colon): 2 people, 33.33%

Common conditions people have *:

Eye Movement Disorder: 3 people, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tribenzor and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .

Related studies

How severe was Gastrointestinal inflammation and when was it recovered:

Gastrointestinal inflammation in Tribenzor

Expand to all the drugs that have ingredients of amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil:

Gastrointestinal inflammation and drugs with ingredients of amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil

Alternative drugs to, pros and cons of Tribenzor:

Tribenzor (1,772 reports)

Common Tribenzor side effects:

Browse all side effects of Tribenzor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastrointestinal inflammation treatments and more:

Gastrointestinal inflammation (7,706 reports)

COVID vaccines that are related to Gastrointestinal inflammation:

Common drugs associated with Gastrointestinal inflammation:

How the study uses the data?

The study uses data from the FDA. It is based on amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil (the active ingredients of Tribenzor) and Tribenzor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.